About STaGE
The Satellite Trials Group of Emory (STaGE) is a consortium of investigators and coordinators located at multiple sites, uniquely situated to support multiple clinical trials at Emory. STaGE members believe in the advancement of scholarly work in keeping with Emory Healthcare’s mission is to serve humanity by improving health through the integration of education, discovery, and healthcare delivery. Clinical research is one of the key components of Emory’s mission statement. STaGE facilitates clinical research through a framework of investigators and coordinators who are cross-trained on each other’s studies, managed by an oversight team. Our satellite hospital approach embraces the idea of study deployment at multiple Emory properties, which allows for greater enrollment potential. We maintain a blend of externally funded studies and internal (investigator-led and unfunded) efforts in a fiscally responsible way to ensure continued operations and allow for growth. STAGE invokes the concept of the various levels and stages of training of our participants. Investigators are not limited to MDs. APPs within Emory are encouraged to initiate or otherwise participate in scholarly work, as are other learners. We offer a STaGE Research elective within the Critical Care APP Fellowship with a curriculum which includes study design, protocol preparation, basic statistics, and regulatory issues. Lectures are provided by STaGE investigators. STAGE emphasizes the three core values of inclusivity, collaboration, and communication. All current and potential investigators are welcomed, and new projects are considered frequently. If a new investigator/project is accepted, we leverage the strengths of our entire research team to facilitate and optimize potential.
What We Do
Trials
- Funded studies: We carefully select our sponsored studies based on feasibility, clinical importance, whether or not we are in a position of equipoise. Our portfolio includes studies that are complimentary to each other, avoiding any potential for cannibalism. Sponsors include pharmaceutical drug companies, device companies, and
- Investigator-initiated and unfunded studies: We maintain a large portfolio of investigator-initiated and unfunded studies, including retrospective analyses, biorepository investigations, quality initiatives, and prospective observational studies. We also support federally and non-profit funded investigator awards.
Investigators
Study Portfolio
Past
To see closed, active, pending, or unsponsored programs, please visit the STAGE DASHBOARD.
- IVY-3
- IVY-4
- IVY-5
- REVIVAL
- VICTAS
- ATHOS EAP
- Suramin
- ENDCOVI
- NECTAR
- STAT-ICU
Current
- IVY-6
- CHiLL
- TIGRIS
- REPAVID
- PRECISE
- RESPIRATIO
Pipeline
- NEPHRO CRRT
- ARCC-NET
- ACCURATE
- In-hospital Freestyle Libre
- TABLO
- Lactate Wearable Tech
- NOVARTIS TIN816
Unfunded Studies
- Renin VICTAS Biorepository study
- Retrospective analysis of Ang II in septic shock
- Renin and DPP3 in shock
- SPiDeR
- CIRCI
- Vasopressor doses and outcomes
- PORK CHOP
- DARK SEPSIS